Molecular Analysis and Treatment Options of Thymic Malignancies

Last updated: May 20, 2025
Sponsor: Shanghai Chest Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Head And Neck Cancer

Carcinoma

Thymomas

Treatment

Chemotherapy

Clinical Study ID

NCT05667948
THORACIC002
  • Ages > 18
  • All Genders

Study Summary

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.

In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically proven diagnosis of thymic malignancies

  • 18 years of age or older

  • Ability to understand and the willingness to sign a written informed consent document

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Chemotherapy
Phase:
Study Start date:
January 01, 2016
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Xiaomin Niu

    Shanghai, Shanghai 200030
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.